RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to boost immunotherapy for head and neck cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) helps people with head and neck cancer that has returned or spread. About 52 adults with incurable, measurable disease will receive either the combo or pembrolizumab alone. The goal is …
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
Promising combo aims to shrink tough head and neck cancers
Disease control OngoingThis study tests whether adding an immunotherapy drug (cemiplimab) to low-dose chemotherapy can shrink tumors in people with head and neck cancer that has returned or spread. About 46 adults who have not had prior treatment for advanced disease will receive the combination. The m…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 17, 2026 03:09 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis study tested whether adding the drug bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread live longer. About 400 adults with this advanced cancer took part. The goal was to see if the combination improves overall survival co…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and cabozantinib, can shrink tumors in people with head and neck cancer that has returned or spread and cannot be removed by surgery. The trial includes 36 adults with certain types of head and neck squamous cell carcino…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy targets Hard-to-Treat head and neck cancers
Disease control OngoingThis study tests whether adding the drug sorafenib to standard chemotherapy (carboplatin and paclitaxel) can help control advanced head and neck cancer that has spread or returned. About 48 adults with this type of cancer will receive the combination treatment. The goal is to see…
Matched conditions: RECURRENT OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:00 UTC